Interview: Hernán Fernández – Managing Partner, Angel Ventures, Mexico

16.05.2017
Hernán Fernández, Managing Partner at Angel Ventures, showcases the crucial role of private investments to enhance the national healthcare system as well as explains his action plan to raise the funds for the first regional venture capital fund in Latin America. Mr. Fernández, what are the points that triggered you to found Angel Ventures Mexico (AVM) in 2008?
"AVM II will have a more regional investment approach and will target early stage projects in countries that are within the Pacific Alliance."
Become a PharmaBoardroom Member for free to access this content
Join the 20,000+ pharmaceutical professionals who already subscribe to PharmaBoardroom
Register
Already a member? Sign In
Tags:
Mexico, Angel Ventures, VC, Venture Capital, Healthcare, Investment

Related Interviews

Constanza Losada – President & CEO, Pfizer Mexico

Recently appointed CEO and president for Pfizer Mexico, Constanza Losada, outlines the exciting challenge of taking on leadership for such an important affiliate during the COVID-19 pandemic and how Pfizer…

Luis Calderon – General Manager, Biogen Mexico

Biogen Mexico’s Luis Calderon discusses establishing the affiliate, the opportunities apparent in the Mexican neurodegenerative disease market, and the impact of the country’s ongoing health reforms.   In my experience,…

Omar Lugo Aguirre – Country Lead, nPVU & Market Access, Operations…

UCB’s Omar Lugo Aguirre outlines the company’s response to the COVID-19 pandemic in Mexico, countering stigmas around neurodegenerative and mental diseases, and the abundant opportunities that Mexico and the region…

Related Articles

Mexico / India Ties Deepen; Lilly COVID Drugs Approved; Lithium Opportunities

The latest from Mexican pharma, including government talks with Indian authorities to provide low-cost medicines, a new distribution pilot program led by the military, the authorization of two Lilly monoclonal…

LatAm / Aligning Stakeholder Partnerships: Best Practices from Cuba & Mexico

Writing in the November issue of DIA Global Forum, Lawrence Liberti, Mario Alanis, Pravin Chopra, and Silvia Bendiner examine how the COVID-19 pandemic facilitated greater inter-stakeholder collaboration across the healthcare…

LatAm / Bayer Bets Big in Costa Rica/Argentina; Mexico Drug Approvals Slow; Pfizer’s Aggressive Supply Deal Tactics

The latest from the healthcare industry in Latin America, including an alarming OECD report about the decline of well-being in the region due to Covid-19, Bayer’s USD 350 million investment…

Latest Report

Singapore Pharma Report 2021

Related Content

Mexico
Angel Ventures
VC
Venture Capital
Healthcare
Investment